Jumaar Chrisstoffel, Jacobs Steve, Payne Carmen, Sanni Olakunle, Louw Elize, Baines Nicola, Maree David, Botha Benjamin, Feyasa Merga Belina, Strijdom Hans, Allwood Brian, Maarman Gerald J
Centre for Cardio-Metabolic Research in Africa, Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Medicine & Health Sciences, Stellenbosch University, Cape Town 8000, South Africa.
Division of Pulmonology, Department of Medicine, Faculty of Medicine & Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town 8000, South Africa.
Infect Dis Rep. 2025 Feb 28;17(2):21. doi: 10.3390/idr17020021.
Despite "successful" treatment, some lung tuberculosis (TB) patients develop long-term lung impairments that includes damage to the parenchyma and reduced function, which may predispose them to diseases like pulmonary hypertension. However, this is not well understood. Therefore, we investigated whether previous or current TB patients would display elevated biomarkers of endothelial dysfunction and vascular remodeling. : We performed assays for ADMA, VCAM-1, VEGF, angiopoietin-1, TBARS, NT-pro-BNP, and cardiac troponin-I. We further stratified the patients based on 1, 2, 3, and >3 previous TB episodes, and 1-5 yrs, 5-10 yrs, 10-15 yrs and >15 yrs after the last TB treatment completion. We also assessed correlations between the biomarkers and the number of previous TB episodes or the time since the completion of the last TB treatment. : ADMA was 70 times higher, VEGF was 2000 times higher and angiopoietin-1 was 6500 times higher than the normal range. NT-pro-BNP and cardiac troponin-I were undetected, and TBARS levels were low. There was a positive linear relationship between the number of previous TB episodes and angiopoietin-1, and between VEGF and the number of previous TB episodes. ADMA, VCAM-1 and TBARS exhibited a weak and negative linear association with the number of previous TB episodes. A negligible negative linear association was observed between the time since the completion of the last TB treatment and angiopoietin-1, VEGF and ADMA. : Therefore, having >1 previous TB episode, despite the successful completion of TB treatment, associates with an increased risk of endothelial dysfunction/angiogenesis or vascular remodeling.
尽管接受了“成功”治疗，但一些肺结核（TB）患者仍会出现长期肺部损伤，包括实质损害和功能减退，这可能使他们易患肺动脉高压等疾病。然而，对此人们了解并不充分。因此，我们调查了既往或现患TB的患者是否会出现内皮功能障碍和血管重塑的生物标志物升高。：我们对不对称二甲基精氨酸（ADMA）、血管细胞黏附分子-1（VCAM-1）、血管内皮生长因子（VEGF）、血管生成素-1、硫代巴比妥酸反应物（TBARS）、N末端脑钠肽前体（NT-pro-BNP）和心肌肌钙蛋白I进行了检测。我们还根据既往1次、2次、3次和超过3次TB发作，以及最后一次TB治疗结束后1至5年、5至10年、10至15年和超过15年对患者进行了分层。我们还评估了生物标志物与既往TB发作次数或最后一次TB治疗结束后的时间之间的相关性。：ADMA比正常范围高70倍，VEGF高2000倍，血管生成素-1高6500倍。未检测到NT-pro-BNP和心肌肌钙蛋白I，TBARS水平较低。既往TB发作次数与血管生成素-1之间，以及VEGF与既往TB发作次数之间存在正线性关系。ADMA、VCAM-1和TBARS与既往TB发作次数呈弱负线性关联。最后一次TB治疗结束后的时间与血管生成素-1、VEGF和ADMA之间观察到可忽略不计的负线性关联。：因此，既往有超过1次TB发作，尽管TB治疗成功完成，但仍与内皮功能障碍/血管生成或血管重塑风险增加相关。
